import
fieldhematopoiet
stem
cell
transplant
hsct
treatment
choic
mani
hematolog
malign
genet
disord
major
patient
human
leukocyt
antigen
hla
ident
sibl
donor
altern
stem
cell
sourc
includ
hlamatch
mismatch
unrel
donor
haploident
relat
donor
howev
altern
donor
hsct
associ
three
major
complic
graft
reject
ii
graftversushost
diseas
gvhd
iii
delay
immun
reconstitut
lead
viral
infect
relaps
area
cover
reviewgraft
reject
risk
gvhd
significantli
reduc
use
intens
condit
regimen
includ
vivo
cell
deplet
well
ex
vivo
cell
deplet
graft
howev
benefit
remov
alloreact
cell
graft
offset
concomit
remov
cell
antivir
antitumor
activ
well
profound
delay
endogen
cell
recoveri
posttranspl
thu
opportunist
infect
mani
amen
convent
smallmolecul
therapeut
frequent
patient
associ
signific
morbid
high
mortal
rate
review
discuss
current
cell
therapi
prevent
treat
viral
infectionsreactiv
posttranspl
reader
gainth
reader
gain
understand
current
state
cell
therapi
prevent
treat
viral
infect
posthsct
introduc
preclin
studi
design
develop
valid
new
manufactur
procedur
intend
improv
therapeut
efficaci
reduc
associ
toxic
take
home
messagereconstitut
hsct
recipi
antigenspecif
cell
produc
either
allodeplet
vitro
reactiv
offer
effect
strategi
provid
immedi
longterm
protect
without
harm
alloreact
infect
substanti
toxic
drive
outgrowth
resist
viral
variant
effect
virus
sinc
use
antivir
improv
virusspecif
immun
infect
frequent
recur
termin
treatment
contrast
reconstitut
hsct
recipi
antigenspecif
cell
offer
effect
nontox
strategi
provid
immedi
longterm
protect
immunotherapeut
strategi
explor
number
group
first
adopt
cell
transfer
protocol
allogen
hsct
set
base
premis
donor
peripher
blood
contain
cell
abl
mediat
antitumor
andor
antivir
activ
hsct
recipi
accordingli
donor
lymphocyt
infus
dli
extens
use
provid
antitumor
lesser
extent
antivir
immun
dli
contain
memori
cell
specif
broad
rang
virus
howev
success
treatment
proport
infect
adenoviru
efficaci
therapi
limit
low
frequenc
cell
specif
mani
common
acut
virus
rsv
parainfluenza
rel
high
frequenc
alloreact
cell
high
ratio
alloreact
virusspecif
cell
especi
problemat
recipi
haploident
transplant
higher
incid
gvhd
limit
toler
dli
dose
sever
limit
dose
virusspecif
cell
receiv
preserv
benefit
enhanc
safeti
dli
strategi
select
remov
inactiv
recipientspecif
alloreact
cell
evalu
induct
anergyantigen
specif
tcell
anergi
induc
ex
vivo
cell
receptor
tcr
signal
absenc
costimul
cell
requir
least
two
signal
becom
activ
signal
involv
tcr
engag
peptideload
mhc
molecul
signal
mediat
costimulatori
molecul
cell
engag
ligand
apc
interact
receptor
cell
ligand
apc
one
major
posit
costimulatori
signal
block
fusion
protein
monoclon
antibodi
guinan
colleagu
investig
whether
blockad
interact
could
use
clinic
render
alloreact
donor
cell
anerg
initi
studi
show
cocultur
whole
bone
marrow
irradi
recipi
cell
presenc
reduc
frequenc
alloreact
cell
reactiv
rd
parti
cell
unaffect
evalu
patient
alloanerg
marrow
could
reliabl
engraft
infus
rel
larg
cell
dose
median
cellskg
associ
excess
gvhd
two
followup
phase
clinic
trial
group
analyz
immun
reconstitut
infect
develop
acut
chronic
gvhd
larger
patient
cohort
receiv
haploident
hsct
ex
vivo
induct
alloantigenspecif
anergi
donor
cell
achiev
use
found
alloanerg
appear
impair
immun
reconstitut
median
absolut
lymphocyt
count
alc
day
l
similar
patient
receiv
unmanipul
bmt
hlamatch
sibl
donor
despit
rel
high
number
anerg
cell
median
cell
dose
kg
associ
increas
incid
steroidrefractori
acut
chronic
gvhd
highrisk
patient
donor
andor
recipi
cmv
seroposit
reactiv
cmv
abl
clear
infect
short
cours
day
antivir
therapi
none
develop
either
cmv
diseas
ebv
ptld
author
current
conduct
followup
studi
use
escal
dose
alloanerg
cell
defin
optim
cell
dose
improv
immun
reconstitut
without
caus
sever
gvhd
comoli
colleagu
investig
similar
approach
induc
alloantigenspecif
cell
anergi
ad
combin
cyclosporin
csa
vitro
primari
mix
lymphocyt
reaction
induc
state
unrespons
recipi
alloantigen
donor
pbmc
leav
antivir
activ
intact
howev
efficaci
strategi
remain
test
clinic
altern
rout
alloantigenspecif
immun
toler
use
inhibitori
suppress
characterist
associ
regulatori
cell
treg
establish
role
treg
prevent
gvhd
allogen
sct
rezvani
colleagu
quantifi
number
treg
donor
graft
infus
hlamatch
sibl
found
high
frequenc
treg
donor
associ
reduc
risk
gvhd
sct
recipi
found
low
cell
count
earli
day
transplant
associ
increas
risk
author
suggest
assessmentof
treg
content
use
predictor
risk
acut
gvhd
ex
vivo
expand
treg
infus
could
prevent
treat
gvhd
end
hoffmann
colleagu
valid
ex
vivo
expans
larg
number
function
treg
use
crosslink
antibodi
togeth
high
dose
recent
translat
clinic
trzonkowski
et
al
adopt
transfer
ex
vivo
expand
treg
two
patient
one
chronic
one
acut
gvhd
infus
associ
clinic
benefit
case
patient
chronic
gvhd
complet
resolut
symptom
achiev
patient
grade
iv
acut
gvhd
show
transient
clinic
improv
select
allodepletiona
potenti
perman
approach
gvhd
remov
alloreact
cell
donor
graft
prior
infus
recipientspecif
cell
activ
vitro
exposur
recipi
cell
ebvtransform
lymphoblastoid
cell
line
ebvlcl
three
clinic
trial
use
allodeplet
cell
report
prepar
use
two
perform
pediatr
recipi
haploident
stem
cell
transplant
one
adult
receiv
hlamatch
relat
donor
transplant
compar
earlier
studi
report
gvhd
grade
ii
greater
patient
infus
unmanipul
donor
lymphocyteskg
andreschmutz
colleagu
found
infus
dose
high
allodeplet
cellskg
safe
retain
virusspecif
immun
compon
sinc
three
infus
patient
activ
cmv
rapid
increas
antigenspecif
cell
postinfus
subsequ
resolut
solomon
et
al
infus
elderli
patient
high
risk
sever
gvhd
allodeplet
cell
eight
patient
develop
acut
gvhd
rang
grade
iii
patient
grade
iiiiv
patient
sever
diseas
correl
effici
deplet
final
amrolia
colleagu
show
infus
allodeplet
cell
haploident
sct
recipi
safe
minimum
dose
cellskg
requir
produc
acceler
antivir
cell
recoveri
taken
togeth
studi
demonstr
feasibl
addback
cell
therapi
clinic
use
also
highlight
number
limit
current
strategi
first
avail
clinic
grade
may
issu
larger
phase
iiiii
studi
second
studi
amrolia
colleagu
recipientderiv
ebvlcl
requir
week
establish
use
cell
allostimulu
ebvlcl
provid
unlimit
sourc
tumorfre
profession
antigenpres
cell
apc
lcl
product
increas
time
requir
cell
prepar
studi
also
demonstr
small
window
minimum
cell
dose
immun
reconstitut
maximum
toler
third
achiev
suffici
cell
infus
challeng
sinc
recoveri
donor
cell
allodeplet
approxim
thu
donor
leukapheresi
may
requir
feasibl
unrel
stem
cell
donor
final
cell
specif
pathogen
circul
lower
frequenc
specif
persist
virus
like
ebv
therefor
even
higher
dose
allodeplet
cell
may
requir
provid
full
spectrum
protect
allow
safe
administr
larger
cell
dose
suicid
transgen
evalu
mediat
self
destruct
case
advers
effect
vivo
thymidin
kinas
gene
herp
simplex
viru
hsvtk
use
valid
clinic
tk
phosphoryl
nontox
prodrug
ganciclovir
becom
phosphoryl
endogen
kinas
gcvtriphosph
caus
chain
termin
singlestrand
break
upon
incorpor
dna
kill
divid
cell
sever
phase
iii
studi
recent
phase
iii
studi
shown
ganciclovir
administr
use
reduc
transfer
tkmodifi
cell
howev
tk
gene
product
may
immunogen
specif
immun
respons
direct
transgen
protein
detect
vivo
may
lead
prematur
unintent
elimin
infus
group
investig
altern
minimallyimmunogen
approach
allodeplet
cell
transduc
retrovir
vector
encod
induc
human
caspas
suicid
select
marker
truncat
human
even
allodeplet
donor
cell
could
effici
transduc
expand
subsequ
enrich
immunomagnet
select
engin
cell
retain
antivir
specif
follow
follow
icasp
activ
smallmolecul
dimer
cell
underw
thu
scaleup
allodeplet
dose
feasibl
current
test
center
haploident
transplant
set
altern
strategi
prevent
treat
specif
viral
infect
hsct
adopt
transfer
ex
vivoexpand
cell
antivir
activ
specif
expans
virusreact
cell
advantag
increas
number
virusspecif
cell
infus
without
increas
alloreact
cell
cytomegaloviru
cmv
cmv
persist
betaherpesviru
frequent
reactiv
recipi
host
tissu
allogen
sct
fatal
pneumon
may
follow
new
infect
reactiv
avail
therapi
may
fail
prove
toxic
riddel
colleagu
infus
vitro
expand
cytomegaloviru
cmv
reactiv
cell
clone
allogen
hsct
patient
prevent
cmv
reactiv
found
cell
safe
abl
restor
antivir
immun
vivo
transfer
cell
persist
least
week
base
cell
receptor
tcr
clonotyp
studi
progress
declin
patient
develop
concomit
endogen
cmvspecif
helper
respons
subsequ
einsel
colleagu
gener
polyclon
cmvspecif
ctl
line
contain
cell
infus
patient
antivir
chemotherapyresist
cmv
viremia
clinic
result
impress
infus
small
number
cell
cellsm
significantli
reduc
viral
load
evalu
patient
effect
sustain
long
term
subject
transient
two
highest
viru
load
cmvdna
copiesml
second
cell
infus
control
infect
complet
one
patient
eventu
succumb
fatal
cmv
enceph
refus
second
dose
ctl
similarli
encourag
result
use
polyclon
cmvspecif
ctl
line
publish
pegg
colleagu
recent
micklethwait
et
al
although
ctl
line
gener
use
differ
antigen
pegg
et
al
use
dc
load
inactiv
cmv
antigen
produc
human
lung
fibroblast
cell
cultur
infect
human
cmv
town
strain
stimul
pbmc
allogen
hsct
donor
sixteen
patient
treat
cultur
cmvspecif
cellskg
median
day
posttranspl
first
episod
cmv
viremia
infus
cell
safe
caus
gvhd
expand
vivo
confirm
tetram
analysi
donor
inform
hla
type
furthermor
cell
appear
effect
result
reconstitut
viral
immun
eight
ten
case
addit
antivir
drug
requir
micklethwait
colleagu
gener
donorderiv
cmvspecif
cell
prophylact
use
adult
hsct
patient
stimul
polyclon
cell
dc
transduc
chimer
adenovir
vector
encod
immunodomin
cmv
antigen
infusionrel
toxic
although
four
patient
reactiv
cmv
titer
low
antivir
therapi
need
achiev
viral
control
epstein
barr
viru
ebv
cell
therapi
also
success
use
prevent
treat
viral
ebv
associ
lymphoprolif
disord
post
transplant
lymphoprolif
diseas
ptld
hsct
solid
organ
graft
although
patient
respond
withdraw
immunosuppress
andor
antib
cell
antibodi
rituximab
diseas
may
progress
fatal
outcom
rooney
colleagu
gener
ebvspecif
ctl
use
ebvlcl
stimul
transfer
immunocompromis
patient
risk
develop
ebvassoci
ptld
sinc
group
infus
sct
recipi
donorderiv
polyclon
cell
line
establish
dose
ctlm
safe
effect
prophylaxi
treatment
similar
approach
use
group
achiev
similar
result
first
patient
enrol
rooney
studi
receiv
ctl
genet
mark
retrovir
vector
contain
neomycin
resist
gene
neo
longterm
followup
show
mark
cell
could
detect
long
year
post
infus
although
effect
major
patient
treat
activ
diseas
ctl
therapi
ebv
fail
except
case
although
ebvlcl
use
apc
express
rang
viral
latent
earli
lytic
antigen
immunogen
hierarch
hla
depend
ctl
line
display
specif
limit
number
epitop
viral
therefor
effort
treat
ebvlpd
may
fail
tumor
mutat
immunodominantvir
target
antigen
major
specif
contain
within
ctl
line
complic
discov
patient
ebvlpd
whose
ctl
line
larg
specif
epitop
delet
tumor
viru
highlight
import
infus
ctl
product
polyclon
broad
antigen
epitop
specif
order
minim
potenti
tumor
immun
evas
multiviru
ctlmore
recent
safeti
efficaci
ctl
line
simultan
target
ebv
cmv
adenoviru
adv
demonstr
hsct
recipi
apc
produc
express
immunodomin
antigen
activ
monocyt
ebvlcl
use
chimer
adenovir
apc
consist
reactiv
ctl
specif
three
virus
singl
cultur
although
specif
domin
cmvreactiv
cell
smaller
fraction
ebvand
adenovirusreact
infus
donorderiv
trivirusspecif
ctl
safe
recipi
hlamatch
relat
unrel
donor
infus
cell
demonstr
appar
activ
three
virus
vivo
strikingli
howev
ctl
direct
ebv
cmv
show
evid
vivo
expans
persist
contrast
adenovirusspecif
ctl
detect
peripher
blood
infus
patient
also
posit
adenovir
cultur
demonstr
import
antigen
vivo
stimulu
infus
cell
howev
none
trivirusspecif
ctl
recipi
develop
adenoviru
infect
contrast
similar
patient
receiv
ctl
suggest
adenovirusspecif
ctl
may
surviv
enter
memori
like
resid
spleen
circul
period
infect
supposit
support
observ
adenovirusspecif
cell
could
detect
first
expand
antigen
restimul
vitro
thu
appear
broad
spectrum
antivir
protect
treatment
provid
singl
infus
cell
small
number
cell
provid
long
term
antivir
protect
although
administr
ex
vivo
activ
expand
antigenspecif
cell
singl
multiviru
specif
appear
safe
effect
mean
prevent
andor
treat
viral
infect
aris
immunocompromis
host
number
limit
broader
implement
cell
immunotherapi
includ
time
taken
produc
clinic
grade
ctl
ii
cost
associ
ctl
product
iii
complex
product
iv
competit
multipl
viral
antigen
hla
molecul
apc
v
wide
rang
virus
requir
coverag
time
manufactur
ctl
linesin
case
ebv
triviru
ctl
gener
ebvlcl
use
apc
requir
week
follow
addit
week
ctl
activ
expans
follow
week
perform
ident
steril
potenc
test
preclud
urgent
treatment
serious
ill
patient
ctl
must
prepar
specul
advanc
patient
judg
high
risk
avail
need
costbesid
infrastructur
cost
build
maintain
gmp
facil
maintain
regulatori
compon
qualiti
assur
qualiti
control
data
manag
number
product
cost
must
also
taken
consider
includ
technician
time
produc
apc
ctl
clinic
use
cost
manufactur
test
clinic
grade
viral
vector
use
genet
modif
cell
apc
reagent
media
ctl
product
releas
test
must
perform
ctl
line
prior
infus
ensur
ident
puriti
potenc
cost
manufactur
test
infus
ebv
ctl
line
gener
triviru
line
exclud
profession
time
although
line
patientspecif
product
note
therapeut
modal
nevertheless
compar
favor
other
exampl
monoclon
antibodi
therapi
treatment
ebvlpd
per
dose
complexityth
product
process
rel
complex
necessit
gener
genet
modif
apc
weekli
ctl
stimul
repeat
feed
open
cultur
system
multipl
skill
judgment
call
also
serv
limit
scalabl
antigen
competitionwhil
studi
trivirusspecif
ctl
could
gener
consist
singl
cultur
line
heavili
domin
cmvreactiv
cell
competit
like
due
combin
factor
includ
lower
frequenc
circul
adenovirusspecif
cell
rel
ebv
cmvspecif
cell
healthi
donor
competit
high
affin
stabl
cmv
ebv
epitop
present
hla
molecul
apc
may
limit
number
organ
singl
ctl
line
reactiv
rang
virus
detect
posttranspl
continu
increas
reagent
becom
avail
screen
detect
tabl
ebv
cmv
adv
bk
viru
clearli
associ
graft
failur
andor
morbid
mortal
posttranspl
recent
identifi
virus
metapneumoviru
bocaviru
though
detect
posttranspl
set
definit
connect
sever
diseas
nevertheless
emerg
virus
must
consid
develop
futur
ctl
protocol
prospect
studi
identifi
caus
factor
posttranspl
morbid
mortal
rapid
ctl
productionth
direct
isol
hlamultimerbind
cell
select
express
cell
follow
stimul
either
recombin
protein
peptid
stimul
allow
rapid
select
virusreact
cell
direct
infus
patient
sever
group
demonstr
small
number
ex
vivo
select
antigenspecif
cell
expand
substanti
infus
hsct
recipi
protect
target
pathogen
median
per
kg
tetram
select
kg
per
kg
cell
select
secret
respons
antigen
stimul
miltenyi
gamma
catch
system
prove
clinic
effect
howev
also
limit
approach
tetram
select
restrict
cell
known
epitop
specif
virus
cmv
high
frequenc
circul
reactiv
cell
assay
provid
hla
unrestrict
mean
select
specif
cell
effector
central
memori
characterist
persist
vivo
mediat
longterm
protect
viral
challeng
howev
low
frequenc
circul
cell
specif
certain
virus
may
limit
tcell
recoveri
one
potenti
approach
enhanc
tcell
recoveri
stimul
cell
combin
whole
antigen
differ
virus
increas
number
activ
select
cell
may
support
surviv
low
frequenc
antigenreact
cell
howev
minimum
effect
dose
infus
yet
establish
third
parti
banksto
bypass
need
grow
ctl
individu
patient
bank
ctl
line
avail
shelf
product
immedi
use
evalu
sinc
unlik
complet
hlamatch
line
avail
close
hlamatch
line
administ
rais
two
potenti
concern
risk
induc
gvhd
administ
rd
parti
ctl
ii
limit
vivo
persist
due
recipi
alloreact
nonshar
hla
antigen
howev
number
small
studi
shown
feasibl
approach
report
clinic
respons
patient
ebv
lymphoma
aris
hsct
solid
organ
transplant
haqu
colleagu
use
rd
parti
ebvspecif
ctl
treat
ptld
solid
organ
transplant
sct
show
encourag
respons
rate
week
month
respect
studi
patient
receiv
dose
ctlkg
weekli
interv
line
select
match
low
resolut
type
screen
high
level
kill
donor
ebvlcl
low
level
kill
patient
pha
blast
degre
hla
match
rang
antigen
statist
signific
trend
toward
better
outcom
closer
match
month
importantli
patient
develop
gvhd
post
ctl
administr
anoth
report
two
solid
organ
recipi
cn
lymphoma
receiv
close
match
ebvspecif
cell
result
complet
resolut
brain
lesion
given
promis
result
use
allogen
ebvspecif
ctl
current
evalu
safeti
feasibl
use
offtheshelf
triviru
ctl
treat
hsct
recipi
cmv
adenoviru
ebv
infect
persist
despit
standard
therapi
multicent
phase
clinic
trial
ctl
line
infus
chosen
base
first
presenc
activ
problem
viru
share
hla
allel
second
overal
degre
hla
match
exampl
would
favor
ctl
line
match
singl
allel
document
antivir
activ
line
match
three
allel
antivir
reactiv
detect
preliminari
result
ten
recipi
receiv
altern
donor
transplant
encourag
none
experienc
acut
gvhd
complet
partial
respons
achiev
evalu
recipi
trend
continu
gener
larger
ctl
bank
cover
mani
racial
group
possibl
progress
phase
ii
clinic
trial
ask
specif
question
regard
persist
function
ctl
vivo
reduc
product
time
increas
efficaci
apcstrivirusspecif
cell
produc
reactiv
peripher
blood
cell
autolog
monocyt
transduc
vector
express
follow
day
restimul
autolog
ebvlcl
transduc
vector
infecti
virus
ebv
ebvlcl
product
clinic
grade
adenovir
vector
requir
ctl
stimul
expens
make
test
reduc
cost
avoid
use
viral
vector
investig
altern
sourc
antigen
evalu
dna
plasmid
encod
antigen
three
virus
introduc
apc
monocyt
dc
use
clinic
applic
amaxa
nucleofect
system
transfer
high
level
transgen
express
achiev
good
apc
viabil
period
cell
activ
plasmid
noninfecti
nonrepl
integr
poorli
transfect
cell
genom
clinic
grade
dna
rapidli
costeffect
produc
scalabl
quantiti
excel
long
term
stabil
estim
substitut
plasmid
reduc
cost
manufactur
elimin
lcl
manufactur
viral
vector
test
test
sinc
cost
plasmid
test
one
tenth
adenoviru
vector
ebv
test
plasmid
also
reduc
antigen
competit
hla
molecul
sinc
apc
nucleofect
separ
plasmid
add
clinic
grade
plasmid
librari
new
protect
antigen
virus
identifi
allow
us
flexibl
increas
spectrum
antigen
target
ctl
need
simplifi
ctl
productionmost
current
protocol
activ
expans
antigenspecif
ctl
ex
vivo
complic
labor
intens
limit
broad
applic
therapi
mani
group
expand
antigenspecif
ctl
clinic
use
well
plate
suitabl
routin
product
larg
cell
number
standard
static
cultur
vessel
depth
medium
limit
oxygen
diffus
volum
limit
suppli
nutrient
concentr
wast
product
includ
lactic
acid
co
result
maximum
cell
densiti
achiev
cellscm
ml
consequ
produc
larg
cell
number
skill
gmp
technologist
must
frequent
divid
cultur
replenish
media
growth
factor
sustain
expans
improv
cell
output
minim
cell
handl
number
closedsystem
bioreactor
explor
mechan
rock
stir
use
increas
avail
cultur
media
nutrient
exchang
perfus
exampl
bioreactor
includ
stir
tank
bioreactor
well
static
hollow
fiber
bioreactor
stir
bioreactor
allow
high
densiti
cell
growth
readili
scale
shear
stress
associ
stir
rate
reduc
cell
viabil
cultur
requir
frequent
medium
sampl
evalu
growthlimit
factor
like
glucos
wast
metabolit
contrast
constant
medium
perfus
hollow
fiber
bioreactor
result
dilut
metabolit
without
shear
stress
cell
sampl
assess
cell
statu
cultur
difficult
high
cell
densiti
also
achiev
cultur
bag
rock
platform
wave
bioreactor
use
jensen
colleagu
therapeut
cell
product
although
gmp
applic
produc
larg
number
cell
disadvantag
cost
purchas
space
requir
special
equip
well
complex
run
maintain
equip
moreov
although
geneticallyengin
mitogenicallyactiv
cell
cultur
bioreactor
proven
ineffici
antigenspecif
ctl
product
sinc
ctl
strict
requir
prolong
interact
apc
feeder
cell
disrupt
mechan
agit
vera
cowork
describ
improv
manufactur
system
virusspecif
ctl
use
optim
cell
seed
densiti
novel
cell
ga
permeabl
rapid
expans
devic
grex
support
medium
largescal
product
cell
clinic
use
vera
et
al
j
immunotherapi
press
use
culturewar
promot
optim
co
exchang
initi
input
volum
medium
increas
turn
increas
avail
nutrient
dilut
wast
product
without
need
cultur
agit
frequent
cultur
feed
continu
medium
perfus
allow
higher
antigenspecif
tcell
densiti
per
unit
surfac
area
achiev
per
cm
compar
per
cm
well
simplifi
product
minim
number
complex
manipul
grex
support
promot
rapid
cell
expans
current
system
increas
addit
enhanc
cytokin
thu
cell
made
avail
infus
sooner
would
otherwis
possibl
import
note
rapid
expans
increas
cell
number
due
reduc
cell
death
rather
increas
cell
divis
thu
ctl
function
exhaust
prior
adopt
transfer
rapid
expans
produc
two
log
expans
virusspecif
cell
concomit
difficult
quantifi
loss
alloreact
cell
favor
ratio
virusspecif
alloreact
cell
also
note
although
grex
devic
probabl
readili
support
product
massiv
cell
number
ctl
per
number
studi
shown
massiv
quantiti
cell
requir
reconstitut
virusspecif
immun
hsct
despit
promis
result
ctl
therapi
hla
match
mismatch
allogen
hsct
set
may
challeng
translat
therapeut
modal
recipi
graft
seroneg
donor
cord
blood
transplant
set
increasingli
import
altern
sourc
hla
mismatch
stem
cell
gener
virusspecif
cell
product
infus
complic
naiv
phenotyp
virusreact
cell
vanishingli
low
frequenc
henc
gener
ctl
requir
prime
extens
expans
naiv
cell
rather
simpl
direct
expans
preexist
virusspecif
memori
cell
popul
modif
tradit
ctl
gener
schema
use
optim
apc
enhanc
cytokin
allow
function
ctl
gener
even
start
popul
whether
ctl
deriv
naiv
cell
vivo
persist
antivir
activ
ctl
peripher
blood
remain
evalu
ideal
viral
antigenspecif
ctl
prepar
allogen
donor
rapidli
select
produc
ctl
number
suffici
reproduc
provid
therapeut
benefit
without
harm
alloreact
requir
small
amount
donor
blood
could
obtain
cryopreserv
time
transplant
even
unrel
donor
ctl
product
protect
wide
rang
infecti
agent
commonli
detect
cmv
adv
ebv
bk
viru
also
less
common
virus
includ
rsv
parainfluenza
tabl
virus
detect
less
frequent
may
season
detect
pattern
taken
togeth
contribut
significantli
patient
care
cost
virusrel
mortal
rate
allogen
hsct
thu
rapidlygener
broadspectrum
ctl
may
offer
costeffect
safe
therapi
previou
section
outlin
variou
improv
ctl
gener
protocol
current
combin
strategi
develop
valid
new
manufactur
procedur
simplifi
shorten
ctl
product
extend
number
virus
target
immunogen
antigen
rang
virus
express
plasmid
nucleofect
dc
monocyt
ctl
expand
grex
devic
support
optim
expans
day
cultur
ctl
test
identifi
steril
function
infus
either
prophylact
therapeut
figur
implement
modif
ctl
product
process
enabl
extens
cell
therapi
broad
spectrum
clinic
relev
virus
use
singl
ctl
product
costeffect
predict
reduct
cost
ctl
manufactur
less
toxic
administ
multipl
antivir
agent
even
abl
deliv
breadth
protect
viral
infect
frequent
hematopoiet
stem
cell
transplant
cell
therapi
offer
effect
nontox
strategi
provid
immedi
longterm
protect
alloreact
cell
must
remov
inactiv
enhanc
safeti
improv
efficaci
donor
leukocyt
infus
adopt
transfer
cytotox
lymphocyt
ctl
line
target
singl
multipl
virus
simultan
prevent
treat
infect
immunocompromis
individu
current
preclin
work
aim
overcom
manufactur
limit
allow
broad
implement
cell
therapi
ctl
manufactur
process
shorten
week
use
plasmid
nucleofect
dc
activ
cell
effici
rapidli
expand
grex
tabl
emerg
viral
pathogen
implic
complic
hsct
sot
